NCT05509894View on ClinicalTrials.gov

Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone

Active, not recruitingOBSERVATIONAL
Enrollment

565

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

January 3, 2028

Study Completion Date

January 3, 2028

Conditions
Pediatric Growth Hormone Deficiency
Interventions
DRUG

Ngenla

As provided in real world practice

Trial Locations (1)

Unknown

Pfizer, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05509894 - Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone | Biotech Hunter | Biotech Hunter